[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507253":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":22,"responsibleParty":43,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Zhongshan People's Hospital, Guangdong, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening cohort",null,"30-69 years old healthy participants in Zhongshan",[13],"Procedure: participants will undergo dual-energy CT and endoscopy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","participants will undergo dual-energy CT and endoscopy","Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy",[9],[21],"Biological\u002FVaccine: Blood and saliva Collect blood and saliva samples from participants",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Zhongshan People's Hospital","RECRUITING","Zhongshan","Guangdong","528403","China","CN",{"type":32,"coordinates":33},"Point",[34,35],113.37912,22.52306,{"lat":35,"lon":34},[38],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"fang Ming Ji, MD","CONTACT","86-0760-89880417","jmftbh@sina.com",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mingfang Ji","Clinical Professor","100507253","screening-effect-of-dual-energy-ct-combined-with-nasopharyngeal-endoscopy-for-screening-nasopharyngeal-carcinoma-100507253",false,"NCT05884983","Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Subject residents in Zhongshan City\n* Subject has no medical record of nasopharyngeal carcinoma\n* Subject is able to comprehend, sign, and date the written informed consent document to participate in the study\n* Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study\n\nExclusion Criteria:\n\n* Subject has heavy cardiovascular, liver or kidney disease\n* Subject has contraindications to nasopharyngeal endoscopy\n* Subject has contrast media allergy",true,"ALL","30 Years","69 Years",{"count":58,"type":59},12000,"ESTIMATED","6 Months","OBSERVATIONAL","All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and dual-energy CT will be performed first for high-risk screening subjects, and dual-energy CT will be performed first for the high-risk group to record dual-energy CT examinations of those suspected of nasopharyngeal carcinoma, and then endoscopy was performed on the high-risk group to record those suspected of nasopharyngeal carcinoma under endoscopy, and finally biopsies were taken for positive lesion sites indicated by dual-energy CT and suspicious lesion sites found by endoscopy to clarify the diagnosis.",[64],"Nasopharyngeal Carcinoma",[66,64,67,68],"Screening","Dual-energy CT","Endoscopy","2025-08-11",{"date":71,"type":72},"2025-08-15","ACTUAL",{"date":74,"type":72},"2023-02-01",{"date":76,"type":59},"2026-12-31",{"name":5,"class":6},1]